Sciwind Biosciences
Hangzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Clinical-stage biotech developing next-generation incretin therapies for metabolic diseases.
Metabolic
Technology Platform
A biologic drug discovery platform focused on engineering novel peptide therapeutics, particularly long-acting and multi-targeting incretin analogs.
Opportunities
Potential to capture significant market share in China and globally with a differentiated, best-in-class GLP-1 therapy.
Risk Factors
High clinical and regulatory risk, with late-stage trials needed to prove superiority over extremely effective established drugs.
Competitive Landscape
A nimble innovator in the fiercely competitive global metabolic drug market dominated by large pharmaceutical companies.